

Lund October 23, 2020

Press Release

Hamlet Pharma-BC Kick-off meeting

The kick-off meeting for a recently funded European Union Horizon 2020 project titled '**HAMLET-BC: A Unique Bladder Cancer Therapeutic, Acting with Great Precision**' was recently held with great success.

This 2-year project falls under the H2020 EIC Accelerator Program to fund projects of for-profit SMEs that have ground-breaking concepts that could shape new markets or disrupt existing ones in Europe and worldwide. The goal of HAMLET-BC project is to accelerate development of Alpha1H as novel treatment for bladder cancer.

Hamlet Pharma provides new cancer treatments based on a peptide-based molecular approach for targeting and killing tumour cells with greater precision. Its proprietary drug complex, HAMLET ('Human Alpha-lactalbumin Made LEthal to Tumour cells') is derived from the human breast milk protein, alpha-lactalbumin, and represents a ground-breaking therapeutic solution with high tumour-killing capacity, high target specificity, killing >40 different types of tumour cells and no demonstrated toxicity. As such, it has the potential to revolutionize cancer treatment.

In the HAMLET-BC project, Hamlet Pharma will advance Alpha1H along the clinical development pipeline as anti-cancer therapeutic for early stage bladder cancer. Recent successful outcomes include initial Phase I/II clinical trial data, proving that Alpha1H acts with high efficacy without any detectable toxicity. With the EIC Accelerator funding, Hamlet Pharma will finalise Phase I/II clinical safety and efficacy studies and advance development of Alpha1H towards a Phase III trial.

For more information, please contact

Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49

catharina.svanborg@med.lu.se

Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57

mats.persson@hamletpharma.com

About HAMLET Pharma

HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared

Lund October 23, 2020

with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α -lactalbumin and oleic acid. Research on mice suggest that local BAMLET treatment may be effective against colon cancer in man.



The project is coordinated by Prof. Catharina Svanborg and CEO Mats Persson of Hamlet Pharma. This project is funded from the European Union's Horizon 2020 research and innovation programme under grant agreement No 954360.

